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Abstract
Background: Recent interest has focused on the potential use of serial interferon gamma (IFN-γ) release assay (IGRA) 
measurements to assess the response to anti-tuberculous (TB) treatment. The kinetics of IFN-γ responses to 
Mycobacterium tuberculosis (MTB) antigens in HIV-infected children during treatment have not however been 
previously investigated.
Methods: IFN-γ responses to the MTB antigens, ESAT-6, CFP-10 and PPD were measured by an enzyme-linked 
immunospot assay (IFN-γ ELISpot) at presentation and at one, two and six months after starting anti-tuberculous 
treatment in HIV-infected children with definite or probable TB. Responses at different time points were compared 
using a Mann-Whitney U test with paired data analysed using the Wilcoxon signed rank test. A Fisher's exact or Chi-
squared test was used to compare proportions when test results were analysed as dichotomous outcomes.
Results: Of 102 children with suspected TB, 22 (21%) had definite TB and 24 (23%) probable TB. At least one follow up 
IFN-γ ELISpot assay result was available for 31 (67%) of the 46 children. In children with definite or probable TB in whom 
the IFN-γ ELISpot assay result was positive at presentation, anti-tuberculous treatment was accompanied by a 
significant decrease in both the magnitude of the IFN-γ response to individual or combined MTB-specific antigens 
(ESAT-6 median 110 SFCs/106 PBMC (IQR 65-305) at presentation vs. 15 (10-115) at six months, p = 0.04; CFP-10 177 (48-
508) vs. 20 (5-165), p = 0.004, ESAT-6 or CFP-10 median 250 SFCs/106 PBMC (IQR 94-508) vs. 25 (10-165), p = 0.004) and 
in the proportion of children with a positive IFN-γ ELISpot assay (Fisher's exact test: ESAT-6 15/0 vs 5/11, p = 0.0002, 
CFP-10 22/0 vs 8/17, p = 0.0001, ESAT-6 or CFP-10 22/0 vs. 9/17, p= 0.002). However almost half of the children had a 
positive IFN-γ ELISpot assay after six months of anti-tuberculous treatment. In addition, there was conversion of the 
IFN-γ ELISpot assay result during anti-tuberculous therapy in six of 12 children in whom the initial IFN-γ ELISpot assay 
was negative.
Conclusions: In HIV-infected children with definite or probable TB, anti-tuberculosis treatment is accompanied by a 
reduction in the magnitude of the IFN-γ ELISpot response to MTB-antigens. However, serial IFN-γ ELISpot 
measurements appear to have limited clinical utility in assessing a successful response to anti-tuberculous treatment in 
HIV infected children.
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Background
Interferon gamma (IFN-γ) release assays (IGRA) based
on the in vitro T cell responses to Mycobacterium-tuber-
culosis  (MTB)-specific antigens have the potential to
improve the diagnosis of tuberculosis (TB) [1]. An
increasing body of evidence, predominantly in immuno-
competent adult populations, shows that IGRA (either
whole blood based (for example, QuantiFERON-TB Gold
assay) or enzyme-linked immunospot (IFN-γ ELISpot),
(for example, T.SPOT.TB assay) have a similar sensitivity
to that of the tuberculin skin test (TST) (between 70-
90%) and a higher specificity for the detection of active
TB disease [2]. IGRA have also been shown to have
higher sensitivity compared to TST for the detection of
active TB disease in HIV-infected persons, with the IFN-
γ ELISpot appearing to be superior to QuantiFERON-TB
Gold in this setting [3].
There is much less data on the use of either IGRA in
children and the sensitivity of the IFN-γ ELISpot and
QuantiFERON-TB Gold for the detection of active TB
disease [4,5] and latent TB infection [6,7] in young chil-
dren has been questioned [8-11]. However, in HIV-
infected children, in whom the performance of the TST is
impaired, studies have shown an IFN-γ ELISpot to have
higher sensitivity than the TST for the detection of active
TB disease [12,13].
In addition to their use as an adjunctive test for the
diagnosis of active TB disease in adults and children,
emerging data suggest a potential role for IGRA in moni-
toring the response to anti-tuberculous treatment. Ani-
mal and human studies have shown a relationship
between the mycobacterial bacillary load and the magni-
tude of IFN-γ responses to MTB-antigens [14,15]. It has
therefore been postulated that a decrease in the magni-
tude of IFN-γ responses to MTB-specific antigens can be
used as a surrogate marker of treatment success [16].
However, studies using serial QuantiFERON-TB Gold or
IFN-γ ELISpot assays measurements in adults taken dur-
ing treatment of either latent TB infection [17-19] or
active TB disease [14,20-30] in various epidemiological
settings have shown conflicting results with IFN-γ
responses decreasing [17,18,20,22,25,26], increasing
[23,24,29,30] or remaining unchanged [21,28] in response
to treatment.
Only three studies have investigated the kinetics of
IFN-γ responses to MTB-specific antigens in children
(two with an IFN-γ ELISpot and one with QuantiF-
ERON-TB Gold In Tube assay) [31-33] and no study has
investigated IFN-γ responses to MTB-antigens during
anti-tuberculous treatment in HIV-infected children.
As part of a prospective study evaluating the usefulness
of an IFN-γ ELISpot assay in HIV-infected children with
suspected TB [12], we investigated the kinetics of T cell
responses to MTB-antigens in a subset of HIV-infected
children with definite or probable TB during anti-tuber-
culous treatment. We hypothesized that successful anti-
tuberculous treatment would be accompanied by a reduc-
tion in the magnitude of the IFN-γ ELISpot response to
MTB-antigens in HIV-infected children with definite or
probable TB that may result in reversion (from positive to
negative) of the IFN-γ ELISpot assay. The aim of the
study was to determine the potential clinical utility of
serial IFN-γ ELISpot assay measurements to assess the
response to treatment in HIV-infected children in a high
TB incidence area.
Methods
Patients
The study was approved by the University of Cape Town
Research Ethics committee (Rec No. 451/2005). The
study population comprised the 22 children with definite
TB and 24 children with probable TB identified from 102
HIV-infected children with suspected TB in a previously
published study [12]. Written witnessed informed con-
sent was obtained from a parent in their preferred lan-
guage. All children were prospectively recruited from
Red Cross Children's Hospital, Cape Town, South Africa
(estimated TB incidence rate 1600/100,000) [34])
between April 2006 and May 2007. HIV-infected children
were classified as having definite or probable TB based on
a combination of well-defined clinical and microbiologi-
cal criteria [12]. Definite TB was defined as isolation of
M. tuberculosis from culture or the detection of acid-fast
bacilli on microscopy of an appropriate site-specific clini-
cal sample. Probable TB was defined as symptoms sug-
gestive of TB and at least two of the following: TB
contact, chest radiograph findings consistent with TB
and good response to TB treatment. An IFN-γ ELISpot
assay was done prior to, and after one, two and six
months of anti-tuberculous treatment.
The IFN-γ ELISpot assay was performed as previously
described [12]. Briefly, peripheral blood mononuclear
cells were stimulated with early secretory antigen target-6
(ESAT-6; a pool of 15-mer peptides overlapping by 10
amino acids, Peptide Protein Research UK; final concen-
tration 5 μg/ml/peptide), culture filtrate protein 10 (CFP-
10, a pool of 15-mer peptides overlapping by 10 amino
acids, Peptide Protein Research, UK; final concentration 5
μg/ml/peptide) and purified protein derivative (PPD,
Evans Vaccines PL00039/0439, final concentration 200
units/ml). No antigen was added to the negative control
well. Anti CD3 mAb CD3-2 (Mabtech) at a final concen-
tration of 100 ng/ml was included as a positive control.
Mean IFN-γ responses to each of the antigens and con-
trols were calculated after subtraction of background
IFN-γ responses obtained from the negative control
wells. IFN-γ responses were expressed as spot forming
cells (SFCs)/million (106) PBMC. The IFN-γ ELISpot wasConnell et al. BMC Infectious Diseases 2010, 10:138
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considered positive if the number of SFCs in the antigen-
stimulated wells was greater than or equal to 5 SFCs/2 ×
105 (25 SFCs/106) above the background response, and, in
cases where the background response was greater than or
equal to 10 SFCs, more than twice the background
response.
Statistical analysis
Data were analysed using Prism Graphpad v5 (Graphpad
software, Inc, San Diego, California, USA). The Mann-
Whitney U test was used to compare nonparametric
unpaired data. The median number of SFCs at each time
point was compared using the Kruskal-Wallis test. Paired
data were compared using the Wilcoxon signed rank test.
A Fisher's exact or Chi-squared test was used to compare
proportions when test results were analysed as dichoto-
mous outcomes.
Results
The demographic details of the patients included in the
study are shown in Table 1. Of the 22 children with defi-
nite TB, MTB culture was positive in 20 (91%). In the two
remaining children AFB were seen on site-specific clini-
cal specimens but cultures were negative. At diagnosis, 12
(26%) children with definite or probable TB were on anti-
retroviral treatment (ART). A further eighteen (39%) chil-
dren commenced ART during the study period.
At least one follow up IFN-γ ELISpot assay result was
available for 31 (67%) of the 46 children with definite or
probable TB. The number of children with definite or
probable TB that had a repeat IFN-γ ELISpot at each of
the three time points is shown in Figure 1. Of the 22 chil-
dren with definite TB, 21 (95%) had an interpretable IFN-
γ ELISpot assay result. Of these 21 children, 15 (71%) had
a positive response to at least one of the MTB-antigens
ESAT-6, CFP-10 or PPD at presentation and 17 (81%)
children returned for at least one follow up IFN-γ
ELISpot assay during anti-tuberculous treatment. Of the
24 children with probable TB, 18 (75%) had an interpreta-
ble IFN-γ ELISpot assay result. Of these 18 children, 12
(75%) had a positive response to at least one of the MTB-
antigens ESAT-6, CFP-10 or PPD at presentation and 14
(58%) children returned for at least one follow up IFN-γ
ELISpot assay during anti-tuberculous treatment. Of the
six children with probable TB whose initial IFN-γ
ELISpot assay yielded an indeterminate result, two had a
persistently elevated background IFN-γ response that
rendered the IFN-γ ELISpot assay result indeterminate
on at least two follow up time points.
At presentation, there was no difference in the propor-
tion of children with a positive IFN-γ ELISpot between
those who had received prior TB treatment and those
who had not (5/11 vs. 20/28, p = 0.15). In children with
definite or probable TB, there was no difference in the
median (interquartile range) CD4% between children
with a positive IFN-γ ELISpot compared to those with a
negative IFN-γ ELISpot (positive 19.12 (10.0-35.5) vs neg-
ative 19.7 (13.6-31.1), p = 0.78).
In the group of children with definite or probable TB
who had a positive IFN-γ ELISpot at presentation, there
was a significant change in median IFN-γ responses to
MTB-antigens during anti-tuberculous treatment (Table
2 and Figure 2 Panel A, B, C). Specifically, there was a
decrease in median IFN-γ responses to ESAT-6 and CFP-
10 and an increase in the response to PPD following six
months of anti-tuberculous treatment, though the change
in response to PPD failed to reach statistical significance
(ESAT-6 median 110 SFCs/106 PBMC (IQR 65-305) vs. 15
(10-115), p = 0.04; CFP-10 177 (48-508) vs. 20 (5-165), p =
0.004; PPD 155 (82-307) vs. 515 (45-1010), p = 0.12). In
addition, there was a decrease in the highest median IFN-
γ response to either antigen (ESAT-6 or CFP-10) follow-
ing six months of anti-tuberculous treatment (highest
response to either ESAT-6 or CFP-10 median 250 SFCs/
106 PBMC (IQR 94-508) vs. 25 (10-165), p = 0.004).
Paired IFN-γ responses to individual antigens were
analysed at the different time points during anti-tubercu-
lous treatment to investigate the within patient kinetics of
IFN-γ responses. In children with definite or probable TB
and a positive IFN-γ ELISpot at presentation, paired anal-
ysis of IFN-γ responses showed a statistically significant
increase in IFN-γ responses to PPD at six months (p =
0.02), decrease in IFN-γ responses to ESAT-6 at two
months (p = 0.01) and decrease in IFN-γ responses to
CFP-10 at two (p = 0.03) and six months (p = 0.02).
In children with definite or probable TB and a positive
IFN-γ ELISpot at presentation, there was a decrease in
Table 1: Demographic details for the patients included in 
the study (n = 46)
Median age in months (IQR) 22.6 (12.4 - 59.6)
Male n(%) 30 (65)
Median weight for age score 
(IQR)
-2.3 (-3.3 - -1.4)
BCG scar present n (%) 33 (72)
Localisation of TB
Pulmonary only 42 (91)
Extrapulmonary TB 1 (2)
Disseminated TB 3 (7)
Median TST induration 
(range) mm
0 (0 - 11)
Median CD4 (IQR) % 20.2 (12.4 - 28.3)
Median absolute CD4 count 
(IQR) cells/ml
712 (392 - 1365)
On anti-retrovirals at 
diagnosis n (%)
10 (22)Connell et al. BMC Infectious Diseases 2010, 10:138
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the proportion of children who had a positive IFN-γ
response to individual antigens ESAT-6 and CFP-10 fol-
lowing six months of anti-tuberculous treatment (Chi
square for trend: ESAT-6 p = 0.006, CFP-10 p = 0.001).
Furthermore, there was a decrease in the proportion of
children who had a positive IFN-γ response to either anti-
gen (ESAT-6 or CFP-10, 22/0 vs. 9/17, p= 0.002). How-
ever, almost half of children had a positive IFN-γ ELISpot
response to ESAT-6 (5/11 (45%)), CFP-10 (8/17 (47%)) or
either ESAT-6 or CFP-10 (9/17 (53%) following six
months of anti-tuberculous treatment. The proportion of
children that had a positive IFN-γ ELISpot response to
PPD remained unchanged during treatment (Table 1).
Of 12 children with definite or probable TB that were
IFN-γ ELISpot negative at presentation, 6 (50%) became
IFN-γ ELISpot positive (i.e. converted rather than
reverted) at one point or more during anti-tuberculosis
treatment, the rest remaining persistently IFN-γ ELISpot
negative during follow-up. The IFN-γ responses at vari-
ous time points during anti-tuberculous treatment in
these children are shown in Figure 3 (Panel A, B and C).
Discussion
Our study is the first to describe the kinetics of IFN-γ
responses to MTB-antigens during anti-tuberculous
treatment in HIV-infected children. We have shown that,
in HIV-infected children with definite or probable TB in
whom the result of an IFN-γ ELISpot assay is positive at
presentation, anti-tuberculous treatment is accompanied
by a significant decrease in both the magnitude of the
IFN-γ response to MTB-antigens and in the proportion
of children with a positive ESAT-6 or CFP-10 response
following six months of anti-tuberculous treatment. We
have also shown that in some children, anti-tuberculous
treatment is accompanied by a transient increase in the
IFN-γ ELISpot to MTB-antigens. The clinical usefulness
Figure 1 Flow chart of recruitment and follow upConnell et al. BMC Infectious Diseases 2010, 10:138
http://www.biomedcentral.com/1471-2334/10/138
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of serial IFN-γ ELISpot measurements for assessing a
successful curative response to anti-tuberculous treat-
ment in this setting is, however , questionable as almost
half of the children had a positive IFN-γ ELISpot assay
result at the completion of anti-tuberculous treatment.
A small number of previous studies in HIV-uninfected
children have provided preliminary data on the effect of
anti-tuberculous treatment on IFN-γ responses to MTB-
antigens in young children [31-33]. In a cohort of South
African children Nicol et al found an increased IFN-γ
ELISpot response to PPD one month after starting anti-
tuberculous treatment followed by a subsequent decline
after three and six months [33]. In a more recent study in
French children, Hermann et al reported a decrease in
the magnitude of IFN-γ responses (measured using
QuantiFERON-TB Gold In Tube (QFT-GIT)) during
anti-tuberculous treatment but found no difference in the
proportion of children that had a positive assay result at
the completion of treatment compared to baseline [32].
Specifically, of 32 children with active TB, 25 had a QFT-
GIT at baseline and 6 months. Although there was a
reduction in the magnitude of the IFN-γ ELISpot
Table 2: IFN- γ ELISpot assay results during anti tuberculous treatment in HIV-infected children
Antigen Baseline 1 month 2 months 6 months
ESAT-6 (n = 15)*
Median (IQR) IFN-γ response (SFCs/106 PBMC) 110 (65-305) 55 (20-267) 35 (25-95) 15 (10-115) p = 0.04†
No (%) children with a positive ELISpot result 15 (100) 9/13 (69) 13/15 (87) 5/11 (45) p = 0.006ϕ
No (%) children with a reduced IFN- γ response 
compared to baseline
11/13 (85) 12/15 (80) 7/11 (64) NA
CFP-10 (n = 22)*
Median (IQR) IFN-γ response (SFCs/106 PBMC) 177 (48-508) 185 (15-500) 40 (27-327) 20 (5-165) p = 0.004†
No (%) children with a positive ELISpot result 22 (100) 13/19 (68) 17/21 (81) 8/17 (47) p = 0.001ϕ
No (%) children with a reduced IFN-γ response 
compared to baseline
11/19 (55) 16/21 (76) 14/17 (82) NA
ESAT-6 or CFP-10 (n = 22)*
Median (IQR) IFN-γ response (highest 
response to either)
250 (94-508) 190 (20-500) 95 (10-115) 25 (10-165) p = 0.004†
No (%) children with a positive ELISpot result 22 (100) 14/19 (74) 19/21 (90) 9/17 (53) p = 0.002ϕ
No (%) children with a reduced IFN-γ response 
to either antigen compared to baseline
14/19 (74) 16/21 (76) 14/17 (82) NA
PPD (n = 14)*
Median (IQR) IFN-γ response 155 (82-307) 185 (27-242) 177 (55-
893)
515 (45-
1010)
p = 0.12†
No (%) children with a positive ELISpot result 14 (100) 10/13 (77) 12 (86) 10/11(91) p = 0.56ϕ
No (%) children with a reduced IFN-γ response 
compared to baseline
6/13 (46) 7/14 (50) 1/11 (9) NA
* Children with definite TB or probable TB who had a positive IFN-γ ELISpot at presentation
† p value indicates difference in magnitude of the IFN-γ ELISpot responses at baseline vs. 6 months (Mann Whitney U test)
ϕ p value indicates difference in the proportion of children with a positive IFN-γ ELISpot assay (Chi Square test)Connell et al. BMC Infectious Diseases 2010, 10:138
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response to MTB-specific antigens in these children with
treatment, the number (proportion) of children with a
positive QFT-GIT assay result was not significantly dif-
ferent (21/25 (84%) at baseline vs. 18/25 (72%) at 6
months, p = 0.5).
In a TB contact investigation, Ewer et al documented a
decrease in the magnitude of IFN-γ ELISpot responses to
ESAT-6 and CFP-10 in 38 TST-positive adolescents fol-
lowing three months of TB preventive treatment of latent
TB infection. In this study, 32 (84%) adolescents
remained IFN-γ ELISpot positive 15 months beyond the
completion of treatment [31].
The findings of our study in HIV-infected children and
the studies in HIV-uninfected children described above
are consistent with data in similar studies in adults. These
studies indicate that the kinetics of IFN-γ responses to
MTB antigens during anti-tuberculous treatment are not
consistent. Of the studies that have reported serial IGRA
(whole blood or IFN-γ ELISpot assay) measurements
prior to, during or at the completion of treatment of
active TB disease in adults, four have shown an increase
[23,24,29,30] and six a decrease [20,22,25-27,35] in the
magnitude of the IFN-γ responses. For example, Ferrand
et al investigated the IFN-γ ELISpot response to ESAT-6
at presentation, during and at the completion of anti-
tuberculous treatment in patients with pulmonary TB
[24]. In this study IFN-γ ELISpot responses to ESAT-6
were higher at the completion of anti-tuberculous treat-
ment than at presentation. Similarly, Ulrichs et al docu-
mented the IFN-γ ELISpot response to ESAT-6 in 10
adult patients with pulmonary TB prior to and 60 days
after starting anti-tuberculous treatment [29]. In these 10
patients, the median IFN-γ ELISpot response to ESAT-6
was significantly higher at 60 days compared to baseline
IFN-γ responses.
In contrast, Aiken et al documented a reduction in the
magnitude of the IFN-γ ELISpot response to ESAT-6 and
CFP-10 respectively in response to anti-tuberculous
treatment in almost 80% of patients with culture proven
tuberculosis [20]. However, in agreement with the find-
ings from our study, over half of the patients in this study
had a positive IFN-γ ELISpot assay result at the comple-
tion of anti-tuberculous treatment. In an Indian study,
Katiyar  et al investigated the kinetics of the IFN-γ
responses to ESAT-6, CFP-10 and TB 7.7 during anti-
tuberculous treatment in 79 adults with confirmed TB by
repeating a QFT-GIT assay at two and 6 months [25]. In
this study, there was a progressive reduction in the mag-
nitude of the IFN-γ response during anti-tuberculous
treatment. The number (proportion) of patients with a
positive QFT-GIT assay result at presentation, two and 6
months was 72 (91%), 46 (59%) and 37 (47%) respectively.
In another study in adults, Carrara et al documented a
decrease in the IFN-γ ELISpot response to ESAT-6 fol-
lowing three months of anti-tuberculous treatment in 13
o f  1 8  p a t i e n t s  w i t h  c u l t u r e  c o n f i r m e d  T B  t h a t  h a d  a
favourable response to treatment [22]. Notably, in the five
remaining patients, all of whom were persistently culture
positive at three months, a reduction in the magnitude of
the IFN-γ ELISpot response to ESAT-6 was observed but
the IFN-γ ELISpot assay result remained positive.
Although various epidemiological factors may have influ-
enced the results of these longitudinal studies in adults,
the most consistent finding is a reduction in the magni-
tude of the IFN-γ response to MTB-antigens during anti-
tuberculous treatment. However in many cases, this
reduction does not result in a reversion of the IGRA
result.
In the current study, almost one third of children with
confirmed TB had a negative IFN-γ ELISpot at presenta-
tion. Despite the reported sub-optimal sensitivity of
IGRA in children, we previously reported that approxi-
mately two-thirds of HIV -infected children with smear
negative TB are IFN-γ ELISpot positive at presentation
[12]. Our study suggests that with successful treatment
(clinical improvement and weight gain at follow up visits),
children who have a positive IFN-γ ELISpot response at
presentation show reduced IFN-γ responses to the MTB-
specific antigens at each follow-up time point. An early
reduction in IFN-γ responses to MTB-specific antigens
may provide a measure of reassurance to the treating
physician and would be of practical relevance in a child
co-infected with HIV and TB in whom assessing the clin-
ical response to treatment may be problematic. In con-
trast, identifying children in whom IFN-γ responses
remain persistently high or in whom responses increase,
may alert the clinician earlier to the possibility of treat-
m e n t  f a i l u r e  a s  a  r e s u l t  o f  d r u g - r e s i s t a n t  T B  o r  p o o r
adherence to treatment. In our study, we observed one
patient to be persistently culture positive two months
into treatment. This was accompanied by a rapid increase
in the IFN-γ response to CFP-10 (data not shown).
In agreement with the findings in our study, IFN-γ
responses to PPD have been reported to increase during
anti-tuberculous treatment in other studies. The reason
behind this is currently unknown. Several authors have
reported interesting differential decay kinetics to the
individual MTB-specific antigens ESAT-6 and CFP-10. In
a large study in Singapore, a significant reduction in
median IFN-γ responses to CFP-10, but not ESAT-6 was
found following six months of isoniazid preventive treat-
ment [17]. Similarly, in another study, a significant reduc-
tion in IFN-γ responses to CFP-10 was found in 40
patients with active TB disease during anti-tuberculous
treatment but there was no change in IFN-γ responses to
ESAT-6 [26].
In our study, we observed an apparent increase in IFN-
responses to MTB-antigens from baseline at some pointConnell et al. BMC Infectious Diseases 2010, 10:138
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during anti-tuberculous treatment (resulting in a conver-
sion from a negative to positive IFN-γ ELISpot assay
result) in 12 children with definite or probable TB. This
may be the result of ongoing MTB exposure or may illus-
trate the complexity of the underlying dynamic immune
response at different time points during anti-tuberculous
treatment.
Figure 2 IFN-γ responses to ESAT-6 (A), CFP-10 (B) and PPD (C) in 
HIV-infected children in whom the ELISpot was positive at pre-
sentation at one, two and six months. P values represent the differ-
ence in median IFN-γ responses (indicated by horizontal solid bar) at 
the different follow up points.
Figure 3 IFN-γ responses to ESAT-6 (A) CFP-10 (B) and PPD (C) in 
children with a initial negative response that became positive at 
some point during follow up.Connell et al. BMC Infectious Diseases 2010, 10:138
http://www.biomedcentral.com/1471-2334/10/138
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There are a number of limitations to our study. Firstly,
the number of children with serial IFN-γ ELISpot results
at each of the different time points was relatively small.
Despite this, we were able to identify definite trends in
MTB-specific immune responses during anti-tubercu-
lous treatment. Secondly, we were unable to assess the
influence of concomitant anti-retroviral treatment (ART)
on IFN-γ ELISpot responses, as the study was not
designed to explore this in any detail. However, only a
m i n o r i t y  o f  t h e  c h i l d r e n  w e r e  o n  A R T  a t  d i a g n o s i s .
Finally, the IFN-γ ELISpot assay used in the study, though
similar to the commercial T.SPOT.TB assay, incorporat-
ing pools of peptides of ESAT-6 and CFP-10 as stimula-
tory antigens, was not a commercial version of the assay.
However, a similar assay to the one used in this study, has
been used in other published studies [33,36].
Conclusion
We have shown that in HIV infected children with defi-
nite or probable TB in whom an IFN-γ ELISpot assay is
positive at presentation, anti-tuberculous treatment is
accompanied by a reduction in IFN-γ responses to MTB-
specific antigens. However, the clinical usefulness of
serial IFN-γ ELISpot measurements to assess a successful
response to anti-tuberculous treatment in HIV-infected
children in a high TB incidence area appears limited.
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